The Devastating Impact of Missing Puberty - James Linehan (#5)

James Linehan was born with hypogonadism and experienced, involuntarily, what it means to have puberty suppressed for years. His account of the developmental, emotional, social and reproductive consequences offers a rare form of long-term observational evidence — precisely what systematic reviews across Europe have identified as lacking in the clinical literature on puberty-blocking treatments. His testimony intersects directly with findings from the Cass Review, the NICE evidence assessment, and regulatory decisions in Scandinavia, each of which concluded that the evidence base for these interventions in healthy adolescents is insufficient.

James Linehan was not born with gender dysphoria. He was born with hypogonadism, a condition in which the body fails to produce the hormones that drive puberty. Where proponents of gender-affirming care describe puberty suppression as a carefully managed, reversible clinical intervention, Linehan's life represents what suppression looks like when it occurs without a reversal plan — when it simply continues, indefinitely. His account functions as a kind of accidental longitudinal study, offering precisely the long-term observational data that clinical trials on GnRH analogues used in gender medicine have consistently failed to generate. The developmental consequences he describes are not theoretical. Remaining physically and emotionally childlike while peers matured left him socially isolated and markedly more susceptible to manipulation by adults. He traces in detail how an absent puberty arrested not only his physical development but his capacity to read social environments, assert limits and form the peer relationships that adolescence normally consolidates. This converges with what developmental psychologists have established: puberty is not merely a biological event but a neurological and psychosocial one. Suppressing it does not pause a neutral clock; it intervenes in a developmental architecture that cannot simply be resumed from the point at which it was interrupted. Linehan addresses fertility with particular force. The claim that puberty blockers are fully reversible has been examined critically by several European health bodies. The UK's National Institute for Health and Care Excellence concluded in its 2020 systematic review that the evidence for GnRH analogues in gender-dysphoric adolescents was of very low certainty across every outcome measured. The independent Cass Review, whose final report was published in April 2024, identified fundamental gaps in evidence for reversibility, bone density, brain maturation and reproductive outcomes. Linehan's own experience of irreversible fertility loss does not stand apart from this evidence base — it illustrates, from the inside, what that evidentiary gap looks like in a human life. The regulatory landscape across Europe has shifted in response to these findings. Sweden, Finland, Denmark and Norway have each restricted or ended the routine clinical use of puberty-suppressing hormones in gender-dysphoric minors following their own national evidence reviews. France's Académie nationale de médecine issued a comparable advisory in 2022. These are not ideological positions; they are regulatory responses to a common finding — that the evidence required to justify these interventions in otherwise healthy adolescents does not meet the standards demanded for other paediatric treatments. Linehan's account of the unusual docility and compliance that accompanied his suppressed puberty adds a dimension that aggregate clinical data rarely capture. The episode closes with Linehan's direct warnings to parents, clinicians and policymakers. He speaks not from political conviction but from decades of living with consequences that were never presented to him, or to anyone on his behalf, as possibilities at the time of treatment. The hosts situate his testimony within the broader movement in European paediatric medicine toward caution, watchful waiting and psychotherapeutic support — and against the framing of puberty suppression as a low-risk, time-buying measure whose effects are simply undone once a decision is made.

The dossier behind this episode

The Dutch protocol: origins and follow-up data

Puberty blockers did not originate as a treatment for adolescent gender distress. Gonadotrophin-releasing hormone agonists, usually abbreviated to GnRH agonists or GnRHa, were already used in paediatric endocrinology to suppress unusually early puberty, and in other branches of medicine for hormone-sensitive conditions. The Dutch innovation was to apply these drugs to adolescents diagnosed with gender identity disorder, later termed gender dysphoria, as part of a staged pathway towards medical transition.

Read the country dossier